All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
The treatment of Acute Myeloid Leukemia (AML) is evolving at a marked pace; resistance to intensive induction chemotherapy causing deaths in elderly patients has sparked these developments. At present, more targeted approaches are being developed where only the malignant cells are eliminated and will hopefully lead to better tolerability and increased efficacy.
Antibodies-based immunoconjugates have been employed to target cell-specific surface receptors. Interleukin-3, granulocyte-macrophage colony-stimulating factor and CD33 receptors have been used as therapeutic targets for AML cells.
In a recent publication in Blood, N. Daver and F. Ravandi from the MD Anderson Cancer Center comment on further advancements in AML treatment with reference to Natural Killer (NK) antibody dependent cellular toxic effects of Fc-engineered CD33 antibodies.
Their commentary is based on data published by Vasu et al. in Blood. Vasu et al. investigated the in vitro efficacy of BI 836858, a fully human, Fc-engineered, anti-CD33 antibody in AML cell lines and primary AML blasts. Vasu et al. reported that BI 836858 demonstrated an anti-leukemic effect through autologous and allogenic NK cell degranulation. It addition, BI 836858 caused NK cell-mediated Antibody-Dependent Cellular Cytotoxicity (ADCC).
In this same study, the authors also compared the difference in BI 836858-mediated ADCC in patients who had received a 10-day course of decitabine therapy (DAC); pre-DAC treatment versus post-DAC treatment. The results showed higher ADCC at day 28 post-DAC treatment compared to pre-DAC treatment. Vasu et al. postulate that this observation occurred as a result of decitabine increasing ligands which activate NK receptors and thus enhancing the ADCC effect of BI 836858 (see figure 1).
The commentary by N. Daver and F. Ravandi states that these results are of significance for AML as two novel antibody based treatment strategies have been identified:
In summary, Vasu et al. conclude that these data provide the basis for a new combination therapy.
Please find the link to the commentary article in Blood.
References